Alvelestat
- Generic Name
- Alvelestat
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22F3N5O4S
- CAS Number
- 848141-11-7
- Unique Ingredient Identifier
- 6Y5629322X
- Background
Alvelestat has been investigated for the basic science of Chronic Obstructive Pulmonary Disease.
AZD9668 Relative Bioavailability
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2010-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01034982
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Efficacy and Safety of Twice Daily 60mg AZD9668 in COPD for 12 Weeks in Patients on Background Budesonide/Formoterol
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 615
- Registration Number
- NCT01023516
- Locations
- 🇸🇰
Research Site, Zilina, Slovakia
A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: AZD9668 Placebo
- First Posted Date
- 2009-07-31
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 838
- Registration Number
- NCT00949975
- Locations
- 🇺🇦
Research Site, Lugansk, Ukraine
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Bronchiectasis
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 38
- Registration Number
- NCT00769119
- Locations
- 🇬🇧
Research Site, New Castle, United Kingdom
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 56
- Registration Number
- NCT00757848
- Locations
- 🇬🇧
Research Site, Liverpool, United Kingdom
A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00703391
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath